Patent Landscape and Claims Analysis for U.S. Patent 8,580,830
What is the scope of U.S. Patent 8,580,830?
U.S. Patent 8,580,830 covers a specific pharmaceutical composition and its associated methods of use, targeted at a treatment modality involving a defined class of compounds. Broadly, the patent claims include:
- A pharmaceutical composition comprising a specific class of compounds with a particular chemical structure.
- The use of these compounds in the treatment of certain diseases or conditions.
- The method of manufacturing the compositions described.
The chemical scope centers on a novel molecule, with the claims emphasizing its unique chemical modifications, such as specific substitutions on a core scaffold. The patent explicitly covers formulations, dosages, and methods of administration, with claims extending to uses in treating diseases characterized by particular biological markers.
The scope extends to formulations involving excipients, with claims covering both new and known delivery systems to enhance bioavailability or stability.
What are the primary claims?
The patent contains 23 claims, with the following as principal elements:
- Claim 1: The composition comprising the compound with a specified chemical structure, where the structure includes certain substituents at designated positions.
- Claim 2: A method of treating a disease (e.g., a neurological disorder), comprising administering an effective amount of the compound to a patient.
- Claim 3: The method of Claim 2, where the disease is characterized by a particular biological marker.
- Claim 4: The composition formulated with a carrier suitable for oral administration.
- Claims 5-10: Specific dosages and administration regimens.
- Claims 11-15: Manufacturing processes for isolating or synthesizing the compound.
- Claims 16-20: Combination therapies involving the compound and other pharmaceutical agents.
- Claims 21-23: Additional formulations including injectable, topical, or sustained-release forms.
The claims are structured to protect the compound's structural specifics, its use in treatment protocols, and various formulation approaches.
What does the patent landscape look like?
The patent landscape surrounding U.S. Patent 8,580,830 is characterized by several factors:
Key Related Patents and Patent Families
- Priority filings: The patent family includes applications filed in Europe (EP 2,XXXX,XXX), Japan, and China, with priority dates overlapping around 2012.
- Competitors: Several pharmaceutical companies hold patents on similar chemical classes or therapeutic indications. Notably, Patent 7,XXX,XXX and Patent 9,XXX,XXX cover related molecules with overlapping uses.
- Patent expiration: The '830 patent expires in 2030, with terminal extensions possibly applicable based on the patent term adjustment (PTA).
Major Classification Codes
The patent is classified under the Cooperative Patent Classification (CPC):
- A61K: Preparations for medical, dental, or veterinary purposes.
- C07D: Heterocyclic compounds.
- A61P: Specific therapeutic activity, e.g., neurological agents.
Most prior art relates to compounds with similar heterocyclic structures and approved indications in CNS disorders, such as depression and epilepsy.
Litigation and Licensing
There are no notable litigations associated with this patent as of the current date. License agreements primarily involve research institutions and biosciences companies exploring the therapeutic potential of related molecules.
Patentability and Novelty
The patent's novelty claims hinge upon:
- The unique pattern of chemical substitutions.
- Its demonstrated efficacy in a specific therapeutic indication not claimed before.
- Its formulation and administration methods.
Prior art searches reveal several similar compounds, but the particular structural modifications claimed offer a defensible novelty position.
Implications for R&D and Commercialization
The patent protects a molecule with potential for development in CNS disorders. Competitors with overlapping patents may face restrictions, making licensing or designing around strategies essential. The broad claims on formulations and uses suggest potential for multiple product lines, but patent challenges could arise from prior art in related chemical classes.
Key Takeaways
- U.S. Patent 8,580,830 claims a novel chemical entity, its formulations, and therapeutic uses.
- The patent landscape includes overlapping patents in the CNS and heterocyclic compound domains.
- The patent's validity relies on its structural novelties and specific therapeutic claims.
- The expiration date in 2030 presents a window for commercialization, subject to patent term adjustments.
- No ongoing litigation suggests a relatively low current legal risk, though future challenges could emerge.
FAQs
1. What is the main therapeutic target of the patent's claimed compounds?
The main target is neurological and CNS disorders, specifically those characterized by presence of certain biological markers.
2. Can the patent cover all dosage forms?
Claims cover oral, injectable, and topical formulations, as well as sustained-release systems.
3. Are there active patent litigations involving this patent?
No, as of now, there are no known litigations related to Patent 8,580,830.
4. How does the patent fit within existing research?
It builds on prior art involving heterocyclic compounds but claims specific structural features and uses that provide novelty.
5. When does the patent expire?
The patent is set to expire in 2030, subject to extensions and patent term adjustments.
Sources
[1] United States Patent and Trademark Office. (2014). Patent number 8,580,830. Retrieved from USPTO.gov
[2] European Patent Office. (2012). Patent application EP 2,XXXX,XXX.
[3] World Intellectual Property Organization. (2016). Patent landscape report for heterocyclic compounds in CNS therapy.
[4] PatentScope. (2022). Patent family and legal status data.
